Business Segments Mega Lifesciences Thailand S.E.

Stocks

End-of-day quote Thailand S.E. 2026-10-06			5-day change	1st Jan Change
33.50 ^THB	0.00%		-2.90%	-

08-24	Mega Lifesciences Public Company Limited, Q2 2026 Earnings Call, Aug 14, 2026
08-13	Mega Lifesciences Public Company Limited Announces Declaration of Interim Dividend for Period from 01 January 2026 to 30 June 2026, Payable on 11 September 2026	CI

Breakdown by Business Segment (THB)

Fiscal Period: December	2021	2022	2023	2024	2025
Pharmaceutical Products
Brands	6.91B	8.06B	8.01B	8.38B	8.74B
Total Assets	4.64B	5.3B	5.58B	5.42B	5.6B
EBITDA	2.01B	2.42B	2.35B	2.47B	2.54B
	-	-	-	-	0
Pharmaceutical Product Distribution
Distribution	6.93B	7.34B	7.41B	6.68B	5.13B
Total Assets	2.93B	3.06B	2.26B	1.75B	1.87B
EBITDA	608M	797M	1.11B	1.44B	1B
	-	-	-	-	284M
Pharmaceutical Contract Manufacturing Services
Original Equipment Manufacture (OEM)	321M	314M	280M	306M	312M
Total Assets	132M	145M	122M	106M	127M
EBITDA	130M	120M	83.33M	106M	102M
	-	-	-	-	0
Unallocated Other Income	10.99M	13.64M	10.86M	17.69M	21.29M
EBITDA	10.99M	13.64M	10.86M	17.69M	21.29M
EBITDA	-	-	-328M	-341M	-431M
	-	-	-	-	0
Total Assets	5.57B	6.14B	6.15B	6.93B	8.16B

Geographical breakdown of sales (THB)

Fiscal Period: December	2021	2022	2023	2024	2025
Southeast Asia	-	13.69B	13.76B	13.23B	11.83B
Total Assets	-	13.27B	12.79B	13B	14.34B
	-	-	-	-	1.07B
Others	354M	1.04B	965M	1.2B	1.24B
Total Assets	50.19M	880M	911M	796M	989M
EBITDA	128M	-	-	-	-
	-	-	-	-	11.83B
Africa	-	949M	961M	913M	1.07B
Total Assets	-	499M	412M	416M	432M
CIS	339M	-	-	-	-
Total Assets	216M	-	-	-	-
EBITDA	23.58M	-	-	-	-
	-	-	-	-	1.24B
Africa and Middle East	892M	-	-	-	-
Total Assets	382M	-	-	-	-
EBITDA	218M	-	-	-	-
Asia Pacific	12.55B	-	-	-	-
Total Assets	12.62B	-	-	-	-
EBITDA	2.38B	-	-	-	-